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Abstract We measured changes in brain magnetization
transfer ratio (MTR) as a potential indicator of myelin
density in brain tissue of patients with relapsing-remitting
multiple sclerosis (RRMS) treated with delayed-release
dimethyl fumarate (DMF) in the Phase 3 DEFINE study.
DEFINE was a randomized, double-blind, placebo-con-
trolled study in which patients with RRMS were random-
ized 1:1:1 to 2 years of treatment with delayed-release
DMF 240 mg twice daily (BID) or three times daily (TID)
or placebo. MTR was analyzed in whole brain and normal-
appearing brain tissue (NABT) at baseline, week 24,
1 year, and 2 years in a subset of patients. MTR data from
392 patients were analyzed. Mean percentage reduction
from baseline to 2 years in median whole brain MTR was
-0.386 % in the placebo group vs increases of 0.129 %
(p = 0.0027) and 0.096 % (p = 0.0051) in the delayed-
release DMF BID and TID groups, respectively. Similarly,
mean percentage reduction from baseline in median NABT
MTR was -0.392 % with placebo vs increases of 0.190 %
(p = 0.0006) and 0.115 % (p = 0.0029) with delayed-
release DMF BID and TID, respectively. Post hoc analysis
of data from patients with no new or enlarging T2 lesions
(n = 147), or who experienced no relapses (n = 238),
yielded similar results. In this analysis, increases in MTR
in brain tissue most likely reflect increases in myelin
density in response to delayed-release DMF. These data in
patients with RRMS are consistent with preclinical studies
that indicate a potential for cytoprotection and remyelina-
tion with delayed-release DMF treatment.
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Introduction
Multiple sclerosis (MS) is a progressive autoimmune dis-
ease of the central nervous system, characterized by
inflammatory demyelination and neuroaxonal degenera-
tion. In relapsing MS, patients experience episodic relapses
associated with neurologic impairment and disability,
affecting overall health and quality of life [1]. Relapses are
unpredictable, but are understood to be associated with
focal inflammation, oxidative stress, and loss of integrity of
the blood–brain barrier [2, 3]. Conventional magnetic res-
onance imaging (MRI) is a sensitive technique for visual-
izing the focal inflammatory lesions of MS. During
relapses, the number of focal lesions detected by MRI
increases [4]. Decreases in the number of acute inflam-
matory lesions in response to treatment are predictive of
the treatment effects of disease-modifying therapies on
clinical relapses [5].
Although conventional MRI scans are very sensitive to
focal white matter pathology in MS patients, diffuse
demyelination and axonal degeneration, with consequent
neurologic impairment, can progress undetected by stan-
dard T1- and T2-weighted MRI imaging techniques [6, 7].
These processes can be detected by non-conventional MRI
acquisition techniques [8]. One of these techniques is based
on the exchange of magnetization between the pool of
protons associated with macromolecules (which are highly
concentrated in the membranes of myelin in the brain) and
protons associated with water molecules [9]. This phe-
nomenon, which is easily quantified using the magnetiza-
tion transfer ratio (MTR), can be used to measure and
monitor changes in myelin density in the brain over time
[10–12].
Changes in the MTR of brain have been shown in ani-
mal models to be sensitive to changes in myelin content;
MTR decreases with acute demyelination and increases
with remyelination [13–15]. Studies performed on post-
mortem brains from patients with MS have also shown a
strong association between MTR measurements and hist-
opathologically measured myelin content [11, 12]. The
MTR of remyelinated lesions differs from both normal-
appearing white matter (NAWM) and demyelinated
lesions, and there is a significant correlation between
myelin content and MTR in both the white matter lesions
and the NAWM [12, 16]. Thus, MTR can be used to detect
changes in myelin density in normal-appearing brain tissue
(NABT) [17] as well as in focal lesions of patients with MS
[11, 18, 19] and may prove to be a useful tool for assessing
the effects of disease-modifying therapies in MS.
Oral delayed-release dimethyl fumarate (DMF; known
as Tecfidera in countries in which it is approved and
referred to as BG-12 during clinical development; also
known as gastro-resistant DMF) was studied in people with
relapsing-remitting MS (RRMS). In two randomized,
double-blind, placebo-controlled Phase 3 studies, DEFINE
and CONFIRM, delayed-release DMF treatment demon-
strated significant clinical and neuroradiologic benefit in
patients with RRMS, including significant reductions in the
number and volume of MRI lesions relative to placebo [20,
21]. In the DEFINE study, delayed-release DMF BID and
TID reduced the mean number of new or enlarging T2
lesions at 2 years by 85 and 74 %, respectively, and the
odds of a greater number of gadolinium-enhancing (Gd?)
lesions at 2 years by 90 and 73 %, respectively, compared
with placebo (all p \ 0.0001) [21]. The mean number of
new non-enhancing T1-hypointense lesions at 2 years was
reduced by 72 and 63 % with delayed-release DMF BID
and TID, respectively, compared with placebo (both
p \ 0.0001) [Arnold et al. co-submitted to J Neurol].
Preclinical studies in tissue and animal model systems
demonstrated pleiotropic anti-inflammatory and cytopro-
tective effects with delayed-release DMF, mediated in part
through induction of the nuclear factor (erythroid-derived
2)-like 2 (Nrf2) antioxidant transcriptional pathway [3, 22].
To assess changes in myelin density associated with
delayed-release DMF treatment in patients with MS,
changes in brain MTR were analyzed in a subset of patients
from the DEFINE study.
Methods
Study design
Full details of the DEFINE study design, including ran-
domization and blinding, have been reported previously
[21]. Briefly, DEFINE was a Phase 3, randomized, double-
blind, placebo-controlled, dose-comparison study con-
ducted in 28 countries over a 2-year period in patients with
RRMS randomized equally to receive oral delayed-release
DMF 240 mg BID, delayed-release DMF 240 mg TID, or
placebo. The primary endpoint was the proportion of
patients who had experienced an MS relapse at 2 years,
assessed in the overall study intention-to-treat (ITT) pop-
ulation (randomized patients who received at least one dose
of study treatment). MRI outcomes were assessed in a
subset of the ITT population at centers with appropriate
imaging facilities (MRI cohort). Secondary MRI endpoints
were the number of new or newly enlarging T2 hyperin-
tense lesions and the number of Gd? lesions at 2 years.
Tertiary MRI endpoints included the effect of delayed-
release DMF, compared with placebo, on MTR at 1 and
2 years.
The DEFINE study was conducted in accordance with
The International Conference on Harmonisation Guidelines
on Good Clinical Practice [23] and the ethical principles
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outlined in the Declaration of Helsinki [24]. Written
informed consent was obtained from all patients before
evaluations were performed to determine eligibility. Sup-
plemental written informed consent was obtained from all
patients who agreed to participate in the MRI portion of the
study.
Patients
Full details of study inclusion/exclusion criteria have
been previously reported [21]. Briefly, patients aged
18–55 years with a confirmed diagnosis of RRMS
according to McDonald criteria [25] and an Expanded
Disability Status Scale (EDSS) score of 0–5.0 were
enrolled. Additionally, there had to be documented disease
activity, with at least one relapse within 12 months prior to
randomization, or a brain MRI scan in the previous
6 weeks showing evidence of at least one Gd? lesion.
Patients were excluded if they had progressive forms of
MS, abnormal parameters in pre-specified laboratory tests,
other major disease that would otherwise preclude them
from participation in a clinical trial, or recent exposure to
other contraindicated medications prior to enrollment.
MRI/MTR methods
Brain MRI scans were performed by blinded MRI techni-
cians at investigational sites whose MRI capability had
been validated by the central MRI reading center (NeuroRx
Research, Montreal, Quebec, Canada) as described previ-
ously [Arnold et al. co-submitted to J Neurol]. All original
digital data for all MRI images were transferred from each
of the sites to the MRI reading center for evaluation by
physicians/technicians who were blinded to the patients’
treatment assignments.
MTR analysis was performed in a subset of patients in
the MRI cohort as not all MRI sites had the capability to
perform MTR assessments. The following MTR data were
collected: median MTR of whole brain and NABT at
baseline; percentage change from baseline in MTR of
whole brain and NABT at week 24, week 48 (year 1), and
week 96 (year 2); mean normalized MTR in Gd? lesion
volume (at week 48 [relative to baseline] and week 96
[relative to week 48]); percentage of Gd? lesion volume
with significantly decreased or increased MTR (relative to
baseline) at week 48 and 96.
Quality assurance
MTR data were required to pass the following pre- and
post-analysis quality assurance rules:
1. Data from 1T scanners were excluded.
2. Data were excluded from patients with valid scans at
only one time point.
3. Data from sites judged unable to provide adequate
MTR images were excluded.
4. Scans were reviewed for image quality upon receipt
and those scans which failed quality assurance were
excluded. Reasons for exclusion included motion
artifact and gross image inhomogeneity on the MTR
image. If consecutive annual scans showed an extreme
change in MTR (more than five standard deviations
from the expected mean), the percentage change for
this timepoint pair was excluded as this MTR change
was considered to be biologically implausible and
likely due to technical artifact, e.g., a failing RF
amplifier.
5. When a software upgrade occurred, the MTR scans
acquired before and after the upgrade were assessed for
evidence of a step function change in MTR that
affected all tissue types. If such a change was detected,
the affected timepoint pair was excluded.
Statistical analysis
Mean percentage change in MTR (relative to baseline) in
whole brain or NABT was compared between treatment
groups using analysis of covariance (ANCOVA), adjusted
for region and baseline whole brain or NABT MTR value.
Data obtained after patients switched to alternative MS
medication were excluded. Missing post-baseline data,
regardless of reasons, were imputed using mean MTR for
each treatment group/visit. Mean normalized MTR in Gd?
lesion volume at week 48 (compared with baseline) and
week 96 (compared with baseline) was also analyzed using
ANCOVA, adjusted for region. The percentage Gd? lesion
volume with significantly increased or decreased MTR on
follow-up scans was compared between treatment groups
using the Van Elteren’s test (stratified Wilcoxon Rank Sum
test with region as the strata). Post hoc analyses of per-
centage change from baseline in MTR of whole brain and
NABT were performed using data from patients who did
not have new or enlarging T2 lesion activity or did not
experience a relapse during the study.
Results
Patients
The MRI cohort of the DEFINE study consisted of 540
patients, 448 (83 %) of whom had exploratory baseline
MTR assessments, and 392 (73 %) of whom had both
baseline and post-baseline MTR evaluations. As reported
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previously, baseline characteristics for the MRI cohort
were similar to the non-MRI cohort and the overall
DEFINE ITT population and were generally comparable
across treatment groups [Arnold et al. co-submitted to J
Neurol]. For the 448 patients who contributed baseline
MTR data, baseline MTR characteristics were similar
between treatment groups (Table 1).
MTR in whole brain and NABT
After 2 years, there was a mean percentage reduction of
0.386 % from baseline in median whole brain MTR in the
placebo group, indicating decreased myelin density. In
comparison, there were mean percentage increases of 0.129
and 0.096 % in the delayed-release DMF BID and TID
treatment groups, a significant improvement compared
with placebo (p = 0.0027 and p = 0.0051, respectively),
suggesting an increase in myelin density (Fig. 1a; Table 2).
At 24 weeks and 1 year, increases from baseline in whole
brain MTR were observed in both the BID and TID
treatment groups that were statistically significant com-
pared with the reductions in MTR that were observed with
placebo.
Similar findings were obtained for the analysis of
median MTR in NABT (whole brain excluding T2-
weighted lesions). The mean percentage reduction from
baseline to 2 years in median MTR in NABT was 0.392 %
in the placebo group, compared with mean percentage
increases of 0.190 and 0.115 % in the delayed-release
DMF BID and TID groups (p = 0.0006 and p = 0.0029 vs
placebo, respectively) (Fig. 1b; Table 2). At 24 weeks and
1 year, increases from baseline in NABT MTR were
observed in the delayed-release DMF treatment groups
while reductions in MTR were observed in the placebo
group; differences with respect to placebo were statistically
significant in both delayed-release DMF groups at both
time points.
The robustness of these findings was confirmed by
sensitivity analyses using observed data prior to the start of
alternative MS treatment, which were consistent with the
primary analyses (Supplementary Table 1).
Post hoc analyses of MTR in whole brain and NABT
were performed in patients with no T2 lesion activity or
those with no relapses during the study. In patients with
no new or enlarging T2 hyperintense lesions during the
study (n = 147), the mean percentage reduction from
baseline to 2 years in whole brain MTR was 0.379 % in
the placebo group, compared with mean percentage
increases of 0.286 % in the delayed-release DMF BID
group and 0.170 % in the delayed-release DMF TID
group (p = 0.0293 and p = 0.0538 vs placebo, respec-
tively) (Table 3). Results were similar for NABT MTR in
patients with no T2 lesion activity. In patients with no
relapses during the study (n = 238), the mean percentage
reduction from baseline to 2 years in whole brain MTR
was 0.347 % in the placebo group, compared with mean
percentage increases of 0.232 and 0.096 % in the delayed-
release DMF BID and TID groups (p = 0.0187 and
p = 0.0869 vs placebo, respectively) (Table 4). Findings
for NABT MTR in patients without relapses were similar.
Post hoc analyses at 24 weeks and 1-year, in patients with
no T2 lesion activity or those with no relapses, were
consistent with the 2-year results, showing reductions
from baseline in both whole brain and NABT MTR in the
placebo group, compared with either increases or no
change from baseline in MTR in the delayed-release DMF
groups. The majority of differences relative to placebo
were statistically significant in the delayed-release DMF
BID and TID groups.
MTR in Gd? lesion volume
The analysis of MTR in Gd? lesions at 2 years included
patients with one or more Gd? lesions at 1-year. Due to
significant suppression of Gd? lesion activity with
delayed-release DMF treatment, data were available for
only 7 patients in each delayed-release DMF treatment
group compared with 29 in the placebo group. No treat-
ment effect on Gd? lesion volume MTR endpoints was
observed with either delayed-release DMF dose. Mean
(median) values of MTR in Gd? lesion volume were:
0.833 (0.840) in the placebo group, 0.800 (0.830) in the







Mean (SD) MTR of whole brain 37.1 (5.7) 37.1 (6.1) 37.3 (6.1)
Median (min, max) MTR of whole brain 34.5 (29, 51) 34.0 (28, 51) 36.4 (28, 50)
Mean (SD) MTR of normal-appearing brain tissue 38.1 (5.6) 38.1 (6.0) 38.3 (6.0)
Median (min, max) MTR of normal-appearing brain tissue 35.3 (29, 52) 35.1 (29, 52) 37.5 (28, 51)
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delayed-release DMF BID group (p = 0.3922 vs placebo),
and 0.781 (0.840) in the delayed-release DMF TID group
(p = 0.3984 vs placebo). Among the evaluable patients
with Gd? lesions at 1-year, differences were not observed
between the placebo group and delayed-release DMF group
in the percentage of Gd? lesion volume that underwent
significant increases or decreases in MTR at 2 years.
Discussion
Delayed-release DMF treatment reduced clinical relapses
in patients with RRMS in the Phase 3 DEFINE and
CONFIRM studies. Analysis of a cohort of patients from
these studies with MRI data demonstrated that delayed-
release DMF treatment led to improvements in lesion
Fig. 1 Mean percentage change from baseline in whole brain (a) and
normal-appearing brain tissue (NABT) (b) magnetization transfer
ratio (MTR). *p \ 0.05, **p \ 0.01, ***p \ 0.001 vs placebo, based
on analysis of covariance, adjusted for region and baseline whole
brain or NABT MTR value
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outcomes compared with placebo in conventional MRI
scans [Arnold et al. co-submitted to J Neurol]. Improve-
ments in MTR were also observed in both whole brain and
NABT in an exploratory analysis of a subset of patients
from the MRI cohort who had MTR data acquired.
The use of MTR to assess changes in brain myelin
density in response to MS treatments in clinical trials is a
relatively new approach that, to our knowledge, has only
been used in relatively small scales studies until now [26].
For example, a recent analysis reported a stabilization of
grey matter and white matter MTR in 20 patients with
RRMS treated with alemtuzumab, compared with a
reduction in MTR in 18 untreated patients from a natural
history cohort, with a statistically significant difference
between groups for grey matter [27]. Our analysis, which
uses baseline and post-baseline MTR data from a subset
consisting of 392 patients in the delayed-release DMF
DEFINE study, represents the largest randomized con-
trolled trial to date to utilize MTR data to study change or
stabilization in myelin density in predominantly NABT
(whole brain or NABT) in response to MS therapy. Results
showed that delayed-release DMF treatment, with either
BID or TID dosing, led to significant increases in whole
brain MTR and NABT MTR, most likely reflecting
increased myelin density. In contrast, patients in the pla-
cebo group exhibited a reduction in whole brain and NABT
MTR, reflecting the expected decrease in myelin density
over time [17]. These findings were evident at 24 weeks
and persisted until the end of the study at year 2.
In relapsing forms of MS, remyelination of newly
formed lesions can occur in between relapses, so to
determine the extent to which normal myelin repair pro-
cesses may have contributed to the MTR changes observed,
we undertook post hoc analyses of MTR data from patients
with no new or enlarging T2 hyperintense lesions, and from
patients with no relapses, during the 2-year period of the
study. Results of these analyses were in accordance with
the findings in the overall MTR analysis population: MTR
values were reduced among patients receiving placebo,
while MTR values in delayed-release DMF-treated patients
improved. These data suggest that any remyelination that
occurred may be due to a treatment effect of delayed-
Table 2 Mean and median
percentage changes from
baseline in MTR
Observed data after patients
switched to alternative MS
medications are excluded.
Missing data prior to alternative
MS medications and visits after
patients switched to alternative
MS medications are included
and imputed using the mean of
the data for each treatment
group/visit. All p values were
for the comparison between the
active and placebo groups,
based on analysis of covariance,
adjusted for region and baseline
whole brain or normal-
appearing brain tissue MTR
value
Placebo (n = 135) Delayed-release
DMF BID (n = 131)
Delayed-release
DMF TID (n = 126)
Whole brain
Week 24
Mean (SD) -0.349 (1.5455) 0.023 (1.3518) 0.203 (1.4156)
Median (min, max) -0.320 (-5.03, 3.70) 0.040 (-4.61, 4.94) 0.345 (-4.38, 5.59)
p value 0.0481 0.0031
1 year (week 48)
Mean (SD) -0.440 (1.4960) 0.149 (1.4519) 0.228 (1.4753)
Median (min, max) -0.440 (-5.21, 2.94) 0.149 (-3.88, 4.43) 0.228 (-4.36, 4.51)
p value 0.0015 0.0003
2 years (week 96)
Mean (SD) -0.386 (1.2596) 0.129 (1.4681) 0.096 (1.4151)
Median (min, max) -0.386 (-4.72, 3.89) 0.129 (-4.47, 4.91) 0.096 (-4.53, 3.58)
p value 0.0027 0.0051
Normal-appearing brain tissue
Week 24
Mean (SD) -0.318 (1.5401) 0.066 (1.2718) 0.227 (1.3849)
Median (min, max) -0.300 (-5.49, 3.44) 0.050 (-4.55, 4.09) 0.227 (-3.44, 5.13)
p value 0.0352 0.0027
1 year (week 48)
Mean (SD) -0.395 (1.4719) 0.165 (1.4297) 0.158 (1.4540)
Median (min, max) -0.395 (-4.91, 3.09) 0.140 (-3.73, 4.26) 0.158 (-4.21, 4.67)
p value 0.0022 0.0027
2 years (week 96)
Mean (SD) -0.392 (1.2582) 0.190 (1.4465) 0.115 (1.4153)
Median (min, max) -0.392 (-4.29, 3.75) 0.190 (-4.34, 4.73) 0.115 (-4.54, 3.88)
p value 0.0006 0.0029
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release DMF on non-lesional tissue rather than due to
natural remyelination of lesions.
The analyses of Gd? lesion volume MTR endpoints
were performed to evaluate whether delayed-release DMF
had an effect on the evolution of Gd? lesions that had
formed at an earlier time point (1-year). However, due to
the suppression of Gd? lesion development with delayed-
release DMF treatment, little data were available and
results of these analyses were inconclusive as a result of the
small sample size.
A limitation of this study is the interpretation of the
extremely small changes in MTR that were measured. The
magnitude of these changes is consistent with that reported
in another analysis of MTR changes over time, in an
untreated cohort [27]. Changes in myelin density of a
fraction of a percent can, in principle, be associated with
physiological fluctuations such as changes in water content
of brain (for example, as a result of inflammation) or
decreases in the relative partial volume of cell types other
than myelin, for example, axons, astrocytes, or microglia.
For these reasons we interpret the observed changes in
MTR as reflecting changes in myelin density. Increases in
myelin density are consistent with remyelination and
decreases are consistent with demyelination, but changes in
myelin density of such small magnitude are not specific for
demyelination or remyelination.
A previous analysis of MRI data from the DEFINE
study has shown that brain atrophy (which reflects axonal
loss [28]) was attenuated by delayed-release DMF BID
treatment [Arnold et al. co-submitted to J Neurol].
Alongside the increases in MTR observed with delayed-
release DMF treatment, these findings are consistent with
observations from preclinical studies showing a neuropro-
tective effect of delayed-release DMF in an animal model
of experimental autoimmune encephalomyelitis [3, 22, 29–
31]. These exploratory analyses support the potential of
MTR measurements for detecting treatment effects in large
clinical studies of MS therapies; in particular, those thought
to have neuroprotective properties that contribute to their
mechanism of action.
Table 3 Mean and median
percentage changes from
baseline in MTR: patients with
no new or enlarging T2 lesions
from baseline to 2 years
Observed data after patients
switched to alternative MS
medications are excluded.
Missing data prior to alternative
MS medications and visits after
patients switched to alternative
MS medications are included
and imputed using the mean of
the data for each treatment
group/visit. All p values were
for the comparison between the
active and placebo groups,
based on analysis of covariance,
adjusted for region and baseline
whole brain or normal-
appearing brain tissue MTR
value
Placebo (n = 38) Delayed-release
DMF BID (n = 58)
Delayed-release
DMF TID (n = 51)
Whole brain
Week 24
Mean (SD) -0.414 (1.7323) 0.280 (1.3531) 0.401 (1.4342)
Median (min, max) -0.245 (-5.03, 3.14) 0.145 (-2.15, 4.94) 0.490 (-2.49, 5.59)
p value 0.0397 0.0134
1 year (week 48)
Mean (SD) -0.506 (1.6290) 0.454 (1.4477) 0.010 (1.2762)
Median (min, max) -0.415 (-5.21, 1.85) 0.305 (-2.28, 4.43) 0.228 (-4.36, 2.98)
p value 0.0019 0.0956
2 years (week 96)
Mean (SD) -0.379 (1.5542) 0.286 (1.4307) 0.170 (1.2885)
Median (min, max) -0.386 (-4.72, 2.37) 0.129 (-2.86, 4.91) 0.150 (-3.92, 2.91)
p value 0.0293 0.0538
Normal-appearing brain tissue
Week 24
Mean (SD) -0.299 (1.8041) 0.294 (1.1928) 0.390 (1.3765)
Median (min, max) -0.015 (-5.49, 3.29) 0.175 (-1.78, 4.09) 0.460 (-2.69. 5.13)
p value 0.0561 0.0247
1 year (week 48)
Mean (SD) -0.413 (1.6068) 0.434 (1.4000) -0.017 (1.2119)
Median (min, max) -0.332 (-4.91, 2.09) 0.165 (-2.45, 4.26) 0.158 (-3.65, 2.46)
p value 0.0042 0.1768
2 years (week 96)
Mean (SD) -0.312 (1.5918) 0.314 (1.3814) 0.171 (1.2528)
Median (min, max) -0.392 (-4.29, 2.52) 0.190 (-3.03, 4.73) 0.115 (-3.92, 2.47)
p value 0.0285 0.0644
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